- |||||||||| Review, Journal: An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults. (Pubmed Central) - Dec 6, 2023
Some monoclonal antibodies, such as dupilumab (anti-IL-4?R?) and tralokinumab (anti-IL13) are already approved for the treatment of moderate-to-severe atopic dermatitis, and numerous articles in the literature have demonstrated their efficacy and safety...Data from phase 2b and phase III clinical trials in moderate-to-severe atopic dermatitis in adults indicate that these drugs have a promising efficacy and safety profile. Monoclonal antibodies currently under investigation will be available in the coming years to enrich the therapeutic choice of new alternatives that are valid both in terms of efficacy and safety.
- |||||||||| Corectim (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma
Trial completion, Enrollment change: DELTA3: Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials (clinicaltrials.gov) - Dec 5, 2023 P3, N=801, Completed, Monoclonal antibodies currently under investigation will be available in the coming years to enrich the therapeutic choice of new alternatives that are valid both in terms of efficacy and safety. Enrolling by invitation --> Completed | N=600 --> 801
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
P3 data, Journal: Tralokinumab Efficacy Over 1 (Pubmed Central) - Nov 28, 2023 P3 Overall, the findings of these trials support efficacy in long-term treatment with novel systemic agents for patients with AD. Tralokinumab treatment provides progressive and sustained improvement over 1 year in the extent and severity of AD in patients with moderate-to-severe AD.
- |||||||||| Review, Journal: Nail Psoriasis & Nail Lichen Planus: Updates on Diagnosis & Management. (Pubmed Central) - Nov 26, 2023
We review consensus treatment recommendations for nail lichen planus, as well as emerging treatments, including JAK inhibitors. We emphasize the need for increased awareness and expanded management strategies for inflammatory nail diseases to improve patient outcomes.
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Review, Journal: A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults. (Pubmed Central) - Nov 13, 2023 Tralokinumab has proven efficacious and well-tolerated in a large proportion of patients confirming its value for treating moderate-to-severe AD from age 12?years onwards; it quickly improves itching and can maintain a high-level of response over time; it can be administered with flexible dosing schedules. Future studies will further clarify the role of IL-13 pathway and which patients would be best suited to tralokinumab, shifting AD treatment into an era of precision medicine.
- |||||||||| Corectim (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma
Considering allergy march countermeasures and the use of delgocitinib ointment () - Nov 9, 2023 - Abstract #JSPACI2023JSPACI_103; The role of IL-13 in the pathophysiology of AD justifies a targeted approach and a wealth of clinical data supports tralokinumab as a new therapeutic option for people with moderate-to-severe AD. Sponsored by Torii Pharmaceutical Co., Ltd
- |||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Streptococcus agalactiae infection in a patient with psoriasis under treatment with an IL-17 antagonist () - Nov 6, 2023 - Abstract #ISDS2023ISDS_301; The aim of this study is to examine whether treatment with brodalumab, an IL-17 antagonist, triggered the S. agalactiae infection in our patient. Therefore, dermatologists should be aware of GBS infections during treatment with IL-17 inhibitors, in order to manage properly patients receiving this class of biologic agents.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Preclinical, Journal: Study the involvement of Langerin in mediating epicutaneous sensitization of atopic dermatitis-like mouse model (Pubmed Central) - Nov 1, 2023 In the PERIOP-01 trial, extended thromboprophylaxis didn Mice were topically treated with calcipotriol (MC903) plus ovalbumin (OVA) on the ears to establish AD mouse models, and mice were divided into wild-type control group, wild-type AD group, Langerin knockout control group, and Langerin knockout AD group...In Langerin knockout mice, compared to wild-type mice, skin erythema, skin tumidness, epidermal thickening, inflammatory cell infiltration were more obvious; the mRNA expression levels of Tslp, Il4, Il13, Il17a and Il22 were upregulated with (8.19
- |||||||||| Fragmin (dalteparin sodium) / Pfizer, Eisai, Innohep (tinzaparin) / LEO Pharma
Trial completion date, Trial primary completion date: STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis (clinicaltrials.gov) - Nov 1, 2023 P4, N=50, Recruiting, Mice were topically treated with calcipotriol (MC903) plus ovalbumin (OVA) on the ears to establish AD mouse models, and mice were divided into wild-type control group, wild-type AD group, Langerin knockout control group, and Langerin knockout AD group...In Langerin knockout mice, compared to wild-type mice, skin erythema, skin tumidness, epidermal thickening, inflammatory cell infiltration were more obvious; the mRNA expression levels of Tslp, Il4, Il13, Il17a and Il22 were upregulated with (8.19 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Oct 2023 --> Oct 2024
- |||||||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Enrollment closed: Residual Disease MEMory in PSOriasis Skin During EnstiLAR (clinicaltrials.gov) - Oct 30, 2023 P4, N=12, Active, not recruiting, Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Oct 2023 --> Oct 2024 Recruiting --> Active, not recruiting
- |||||||||| Review, Journal: IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. (Pubmed Central) - Oct 28, 2023
monoclonal antibody, is the only approved biologic agent for HS, obtaining a therapeutic response in only 50% of HS patients...Both bimekizumab and secukinumab, targeting IL-17 in different manners, have successfully completed phase III trials with promising results; the latter has recently been approved by EMA for the treatment of HS. The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease.
- |||||||||| orismilast oral (LEO 32731) / UNION Therap
Enrollment closed: Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) (clinicaltrials.gov) - Oct 27, 2023 P2b, N=210, Active, not recruiting, The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease. Recruiting --> Active, not recruiting
- |||||||||| Innohep (tinzaparin) / LEO Pharma
THE ICEBERG METAPHOR: DIAGNOSIS AND SUBSEQUENT MANAGEMENT OF CONCOMITANT STROKE, VTE AND MALIGNANCY () - Oct 26, 2023 - Abstract #WSC2023WSC_1032; This complex case highlights the importance of consider- ing the multifactorial aetiology of thrombi; particularly malignancy. It is to be pondered upon that the management of this patient was not guided by evidence from a randomised control trial but rather through the art of practicing medicine - a skill that is gained only by experience.
- |||||||||| Retrospective data, Journal, Head-to-Head: Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis. (Pubmed Central) - Oct 23, 2023
The interleukin-17A inhibitor ixekizumab has the highest rate of complete nail clearance and it can be considered the best-ranked therapy from the present evidence. This study is relevant to daily practice as it facilitates the decision when choosing between the wide variety of available biologics in patients for whom clearance of nail symptoms is the first concern.
- |||||||||| temtokibart (LEO 138559) / LEO Pharma
Clinical response to IL-22RA1 blockade is associated with reduction of systemic inflammation () - Oct 10, 2023 - Abstract #ISDS2023ISDS_125; P2a Blockade of IL-22RA1 resulted in significant reduction of a broad range of tissue secreted chemokines, known to drive immune cell recruitment and activation. This supports that the clinical response observed after 16 weeks of temtokibart treatment was associated with decreased systemic inflammation.
|